Condiciones de salud que Milenrama puede ayudar a apoyar.
German Commission E and ESCOP approve yarrow for dyspeptic complaints including mild, spasmodic gastrointestinal discomfort. Flavonoids produce smooth-muscle spasmolysis via calcium channel blockade, and the extract demonstrates prokinetic activity in gastric motility models.
Yarrow is consistently characterized as a strong antioxidant source across peer-reviewed reviews and analytical studies. Its flavonoids (apigenin, luteolin, rutin), phenolic acids (caffeic acid, chlorogenic acid, dicaffeoylquinic acids), and essential oil components suppress ROS production and restore antioxidant enzyme activity.
Animal studies demonstrate that A. millefolium hydroalcoholic extract produces anxiolytic-like effects in elevated plus-maze and marble-burying tests, acting through GABA-A/benzodiazepine receptor modulation. Traditional Brazilian folk use specifically employs yarrow infusions for 'calmness.' No human clinical trials on anxiety exist.
Yarrow is approved by the German Commission E and ESCOP for loss of appetite and dyspeptic complaints. Its bitter constituents and flavonoids act as digestive stimulants, encouraging bile flow and gastric tone. This official recognition is backed by documented pharmacological activity.
Yarrow is used in traditional medicine specifically for overactive respiratory conditions including asthma, and its bronchodilatory mechanism — calcium channel-dependent tracheal smooth muscle relaxation — has been demonstrated in guinea pig models. Evidence is preclinical only.
Yarrow extracts demonstrate antihypertensive and vasorelaxant effects in spontaneously hypertensive rat models, mediated by sesquiterpene lactones leucodin and achillin through calcium channel blockade and endothelium-dependent NO/cGMP-dependent pathways. Used traditionally for hypertension in Mexican and European folk medicine.
Preclinical studies, including a 2020 PMC-published animal study, show yarrow hydroalcoholic extract significantly reduces blood glucose in streptozotocin-induced diabetic rats, performing comparably to metformin. Mechanistic work identifies alpha-glucosidase inhibition, insulin sensitization, and insulin secretagogue activity. No controlled human trials exist.
Animal studies demonstrate that A. millefolium extract inhibits carbachol and potassium-induced bronchoconstriction in guinea pig tracheal preparations, producing bronchodilatory effects. Traditional use for respiratory conditions is widespread, and the plant has expectorant properties attributed to its essential oil.
In a 2020 PMC study in STZ-diabetic rats, yarrow hydroalcoholic extract significantly reduced total cholesterol and LDL-cholesterol while increasing HDL-cholesterol, with effects comparable to metformin. The anti-hyperlipidemic effect is corroborated by earlier Achillea species pharmacological reviews.
Yarrow contains sesquiterpene lactones, flavonoids (apigenin, luteolin), and terpenes (camphene, limonene) that inhibit COX enzymes, prostaglandin E2 synthesis, NF-κB, and human neutrophil elastase, constituting a well-documented multi-target anti-inflammatory profile. Both in vitro and in vivo data support this action.
Yarrow demonstrates vasodilatory, antihypertensive, and vasoprotective pharmacological activity in multiple preclinical models, mediated by calcium channel blockade, endothelial NO release, and flavonoid-driven peripheral vasodilation. It is described in European herbalism as a circulatory stimulant and peripheral vasodilator.
ESCOP formally approves external use of yarrow for mild inflammation of skin and mucous membranes. The 2017 double-blind randomized study showed yarrow oil extract restored inflamed skin parameters (capacitance, pH, erythema) at 3 and 7 days. Its sesquiterpene lactones and flavonoids inhibit inflammatory mediators in skin tissue.
In vitro studies have demonstrated estrogenic activity of A. millefolium, attributed to its flavonoid content. This provides a plausible mechanistic basis for its traditional use in female reproductive conditions, though human clinical data specifically on estrogenic endpoints are lacking.
Yarrow is approved by the British Herbal Pharmacopoeia and the German Commission E for fever management. Its diaphoretic action — promoting perspiration via peripheral vasodilation — is its classical antipyretic mechanism and has centuries of documented ethnopharmacological use across Europe, North America, and Asia.
Yarrow is approved by the German Commission E for liver and gallbladder complaints, and its choleretic activity — stimulating bile flow — has been demonstrated in isolated perfused rat liver experiments. Dicaffeoylquinic acids are identified as the principal choleretic compounds.
A clinical trial in 60 IBS patients using an herbal combination including yarrow demonstrated reduced stomach pain and bloating. Yarrow's spasmolytic, prokinetic, and anti-inflammatory properties provide mechanistic support, and it is traditionally indicated for spasmodic gut conditions.
Yarrow has documented emmenagogue activity and has been used across multiple traditional systems for amenorrhea and irregular menstruation. Clinical trials show it reduces dysmenorrhea pain and menstrual bleeding irregularities, and ESCOP approves it for spasms associated with dysmenorrhea.
Yarrow demonstrates hepatoprotective activity in animal models, reducing liver enzyme elevations and toxic liver injury. Its choleretic action (Commission E approved) supports hepatic clearance. The 2020 PMC study showed improvements in liver enzymes in diabetic rats treated with yarrow extract.
Yarrow (Achillea millefolium) is traditionally called the 'nosebleed plant' and has been used topically to staunch nasal bleeding across European and Native American traditions for centuries. A randomized, double-blind, placebo-controlled trial of 50 patients with recurrent idiopathic epistaxis evaluated intranasal Achillea millefolium ointment over 10 days, supporting its hemostatic efficacy. Its tannins, flavonoids, and the alkaloid achilleine confer astringent and styptic activity.
A controlled study in 334 female students showed yarrow extract significantly reduced overall PMS symptom scores and pain severity versus placebo over three months. This constitutes direct clinical evidence for yarrow in premenstrual syndrome.
Yarrow (Achillea millefolium) is classified in Karger's 2026 rosacea plant extract review as having clinical evidence in rosacea-related dermatological conditions. Its polysaccharide fraction (Am-25-d) reduces nuclear NF-κB concentration—a key early-stage rosacea inflammatory driver—in preclinical models. It contains anti-inflammatory flavonoids, phenols, and terpenoids.
Yarrow extract inhibits elastase and collagenase enzymes, protects against UV-induced oxidative damage, and shows tyrosinase-inhibitory and ROS-scavenging activity in skin cells — all mechanistically relevant to anti-aging. Scientific literature characterizes its skin-rejuvenating properties with supporting in vitro evidence.
Yarrow extract stimulates fibroblast proliferation and collagen synthesis in vitro, and inhibits collagenase and elastase enzymes. Topical creams accelerate collagen-dependent wound healing in animal studies. These actions directly support skin elasticity maintenance.
The 2020 PMC rat study (STZ diabetes model) showed yarrow extract significantly reduced serum triglycerides alongside total cholesterol and LDL, with effects comparable to metformin. The evidence is preclinical only.
Yarrow essential oil and extracts have demonstrated gastroprotective effects against ethanol-induced gastric ulcers in rat models via Nrf2/HO-1 pathway activation. The German Commission E lists spasmodic gastrointestinal ulcers among medical indications, and preclinical evidence of anti-ulcer activity is well-documented.
Yarrow has documented wound-healing activity supported by in vivo animal studies, a double-blind randomized human skin study, and fibroblast proliferation data in vitro. The ESCOP monograph approves external use for small wounds. Traditional use as a vulnerary spans thousands of years globally.
Yarrow (Achillea millefolium) has traditional use in European and North American herbalism for abscesses and infected wounds, taken as an herbal tea and applied topically. It is referenced in herbalist databases as a remedy for bacterial infections with abscess involvement.
Yarrow is traditionally used for rheumatic pain and joint inflammation across Persian and European folk medicine. Its anti-inflammatory (COX inhibition, PGE2 suppression) and analgesic pharmacology provides a plausible mechanism, though no human clinical trials on arthritis endpoints exist.
Yarrow has traditional use for burns and scalds across multiple systems, cited in Persian, European, and Middle Eastern folk medicine. Its wound-healing, anti-inflammatory, antimicrobial, and astringent properties provide a coherent pharmacological rationale for burn management.
Yarrow (Achillea millefolium) is approved by Commission E and ESCOP for fever and cold. It has been used in European, Asian, and Native American herbal traditions as a diaphoretic for febrile illness including cold and flu. Sesquiterpene lactones, flavonoids, and essential oil constituents provide anti-inflammatory and antipyretic effects. EBSCO includes yarrow as a proposed natural treatment for cold and flu.
Yarrow has a long tradition of use for diarrhea and dysentery across Persian, Iranian, North American indigenous, and European folk medicine, attributed to its astringent tannin content and antimicrobial essential oil. No clinical trials specifically on diarrhea have been published.
Yarrow is traditionally employed for eczema and related inflammatory skin conditions, supported by its documented anti-inflammatory, antimicrobial, and skin-soothing pharmacology. ESCOP approves external use for mild skin inflammation, which encompasses the eczematous spectrum. No human RCTs on eczema specifically have been published.
Yarrow is traditionally used for gastritis across multiple cultures, supported by documented gastroprotective pharmacology in animal models. Preclinical studies show protection of the gastric mucosa via anti-inflammatory, antioxidant, and antisecretory mechanisms, but no human clinical trials on gastritis specifically exist.
Yarrow (Achillea millefolium) has been used since ancient Greece and throughout European and indigenous North American herbal traditions as a hemostatic herb for heavy menstrual bleeding, named after Achilles who reportedly used it to stop soldiers' wounds. Its tannin content is thought to constrict blood vessels. Modern scientific evidence from RCTs specifically for menorrhagia is lacking, though wound-healing and astringent properties are pharmacologically documented.
Yarrow is used traditionally for hemorrhoids in West Azerbaijani, Persian, and European folk medicine. Its astringent, anti-inflammatory, and hemostatic properties provide a pharmacological rationale, and it appears alongside hemorrhoids in traditional indication lists in the published literature.
Yarrow has traditional use as a mild sedative and calming herb, referenced in folk medicine and cited in the published literature as used for insomnia and anxiety. Its documented GABA-A receptor activity provides a mechanistic rationale. No clinical trials on sleep endpoints have been conducted.
Yarrow is traditionally used in several systems for menopausal complaints, and its documented in vitro estrogenic activity provides a plausible mechanistic basis. European and Middle Eastern folk use mentions it for female hormonal regulation including menopausal symptoms, but no specific human clinical trials on menopausal endpoints have been published.
Yarrow (Achillea millefolium) is listed among herbs reported effective for dysmenorrhea and menstrual disorders in a PMC systematic review. It has been used as an emmenagogue and antispasmodic for menstrual cramps in European and indigenous North American herbal traditions for centuries. Its flavonoids and alkaloids provide anti-inflammatory and antispasmodic activity.
The aerial parts of yarrow are traditionally used for phlegm conditions and as an expectorant in European, Persian, and Chinese herbalism. Its essential oil contains 1,8-cineole, a documented mucolytic, and the herb is traditionally combined with elderflower and peppermint for respiratory congestion.
The same traditional framework and in vitro estrogenic data that apply to menopause extend to perimenopause. Traditional European and Persian herbal practice includes yarrow as a female hormonal regulator, but dedicated perimenopausal clinical studies do not exist.
Yarrow (Achillea millefolium) is explicitly included in traditional pleurisy herbal formulas, referenced in multiple herbalist sources in combination with pleurisy root, elecampane, and marshmallow root. Herbalist practitioners historically used yarrow for its diaphoretic and anti-inflammatory properties relevant to the fever and inflammation of pleurisy. It is listed as part of the Pleurisy Mix by McDowell's Herbal Treatments.
Yarrow is traditionally used for skin rashes and inflammatory reactions and is described as 'anti-allergic' in classical herbal monographs. Its anti-inflammatory and antihistaminic-flavonoid content supports this use; the Commission E approves topical use for skin inflammation.
Yarrow is traditionally used as a diuretic and for urinary complaints in Persian and European folk medicine. Published pharmacological reviews document diuretic activity in animal models, and chitosan nanoparticles of A. millefolium have been proposed for targeted delivery in urolithiasis.
Traditional Chinese medicine and European folk medicine have used yarrow for varicose veins, linked to its venotonic and vasoprotective properties. A standardized extract has demonstrated vasoprotective activity in preclinical research.
Yarrow has traditional use as a diuretic across multiple herbal systems, with aerial parts specifically employed to increase urine output and relieve fluid retention. A diuretic effect has also been demonstrated in animal studies.
Volver